PDE3 Inhibitors
1 drugsAbout PDE3
Phosphodiesterase 3 (PDE3) is an enzyme that regulates intracellular levels of cAMP and cGMP by hydrolyzing these cyclic nucleotides. This influences physiological processes like smooth muscle contraction, platelet aggregation, and cardiac function.
PDE3 is a target of interest for drug development due to its involvement in various physiological processes. Currently, there is no genetic evidence directly linking PDE3 to specific diseases.
There is one FDA-approved drug, OHTUVAYRE, targeting PDE3, a small molecule developed by Verona Pharma for respiratory conditions. OHTUVAYRE was first approved in 2024.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Acute Myeloid Leukemia, Adult with only 1 trials.
Top PDE3 Drugs
Verona Pharma is the only company with an approved drug targeting PDE3.
Low competition suggests an opportunity for new entrants, but also highlights potential market risks.
PDE3 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PDE3, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
PDE3 Clinical Trials 11 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 6 | 3 | 0 | 3 | 100% |
| Phase 3 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
PDE3 Drug Approval Timeline (2024 - 2024)
The first and only drug targeting PDE3, OHTUVAYRE, was approved in 2024.
Recent approval indicates renewed interest in PDE3; monitor clinical trials for emerging competition.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (11 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting PDE3.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities